"A" for effort and...
...possibly for content. I have just "skimmed" Bioniche's newsletter I just received by email. I really like what I am seeing. I assume this is the first edition as I have never seen/ received before. As noone as mentioned it, here is the opening paragraph (below). A four page newsletter with a solid overview and nice visual of pipeline to end with. Don't have a link (just a pdf received by email) so cannot share. Maybe on website. Definitely worth emailing Jennifer Shea for a copy.
Now, we're communicating!!! rg
Dear Shareholders, Bioniche is very pleased to end the third quarter of the 2012 financial year with a major announcement regarding the receipt of US$20 million in funding from Capital Royalty, L.P, a U.S.-based healthcare investor. This non-dilutive, five-year loan will facilitate Bioniche’s corporate growth and support its capital requirements over the years ahead. We are now well-positioned to deliver on our objectives. We are continuing to supply a formulation of MCC, UrocidinTM, to Endo Pharmaceuticals for use in the ongoing Phase III clinical program. We are also building our core Animal Health franchise and we are seeing positive trends in Animal Health product sales. We are looking to introduce a new canine oncology product and an anti-anxiety product for dogs to the market over the coming months. In addition, our internal review of capital expenditure priorities has led to a reduction in the cash burn rate and we remain committed to a zero cash burn rate in Fiscal 2013. We would like to thank our loyal Shareholders for their continued support in these difficult market conditions and we look forward to an exciting year ahead for Bioniche.